IDNA News and Press, iShares Genomics Immunology and Healthcare From 12/07/21

ARKG provides exposure to the high growth areas of gene therapy, bio-informatics, bio-inspired computing, and molecular medicine. The strategy was very successful in the past 2 years. However, the strategy has underperformed the S&P 500 YTD, and investors are now pulling out their...

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...

Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation’s market share has grown, investment capacity - as measured by average days to trade - also has improved significantly. We believe that as innovation platforms evolve...

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November

We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...

Analysts report that TV viewership is up year over year. One ecosystem operated by a provider they trust is better than multiple apps and passwords all over the web, PYMNTS consumer research finds. The Fed Reserve issued a proposed rulemaking in March of 2021 that would modify the...

In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September